• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development

    8/29/25 5:47:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EXEL alert in real time by email

    – Dr. Aftab has served for over 25 years at Exelixis and has been instrumental in driving the company's scientific innovation and development activities –

    Exelixis, Inc. (NASDAQ:EXEL) today announced it has appointed Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. In this new role, Dr. Aftab will oversee all aspects of the company's drug discovery, translational research, product development and medical affairs activities.

    "Dana has been an integral part of the Exelixis team for more than 25 years, with deep expertise that spans the drug discovery and development continuum. He's been a key contributor to many of Exelixis' most important milestones, including the discovery, development and introduction of cabozantinib, which he and the broader Exelixis team grew from an initial orphan drug indication into a global oncology franchise," said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. "Dana is an excellent choice to lead Exelixis' wide-ranging product development organization as the team maximizes the opportunities for our portfolio, which in addition to cabozantinib includes zanzalintinib, our third-generation oral tyrosine kinase inhibitor that is the subject of multiple pivotal trials, as well as our earlier stage pipeline of promising small molecules and biotherapeutics."

    Dr. Aftab joined Exelixis in 1998, and since then has played a key role in the discovery and development of the company's flagship medicine, CABOMETYX® (cabozantinib), which is currently the leading tyrosine kinase inhibitor in the U.S. for both the treatment of advanced renal cell carcinoma and advanced neuroendocrine tumors. During his tenure at Exelixis, Dr. Aftab held diverse roles across the company's research and development organizations, and most recently served as Executive Vice President, Discovery and Translational Research and Chief Scientific Officer since December 2022. In that role he has overseen the development of the company's early pipeline, as well as of the translational medicine and clinical pharmacology teams supporting work streams across the spectrum of discovery research and product development. Dr. Aftab holds a Ph.D. degree in pharmacology from Yale University and conducted postdoctoral work at the University of California, Berkeley in the field of oncogene signaling.

    Amy Peterson, M.D., who served as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer since August 2023 has departed Exelixis.

    About Exelixis

    Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules and biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.

    Forward-Looking Statements

    This press release contains forward-looking statements, including, without limitation, statements related to Exelixis' senior officer transitions. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation, factors affecting Exelixis discussed under the caption "Risk Factors" in Exelixis' Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 11, 2025, and in Exelixis' subsequent filings with the SEC. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.

    Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250829389096/en/

    Investors Contact:

    Susan Hubbard

    EVP, Public Affairs and

    Investor Relations

    Exelixis, Inc.

    (650) 837-8194

    [email protected]

    Media Contact:

    Hal Mackins

    For Exelixis, Inc.

    (415) 994-0040

    [email protected]

    Get the next $EXEL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EXEL

    DatePrice TargetRatingAnalyst
    7/8/2025$45.00 → $50.00Outperform → Sector Perform
    RBC Capital Mkts
    6/24/2025$60.00Equal-Weight → Overweight
    Stephens
    2/24/2025$36.00Overweight → Equal Weight
    Wells Fargo
    1/27/2025$30.00 → $40.00Equal-Weight → Overweight
    Morgan Stanley
    1/24/2025Outperform → Perform
    Oppenheimer
    12/20/2024$36.00 → $40.00Outperform → Market Perform
    BMO Capital Markets
    12/17/2024$35.00 → $39.00Buy → Neutral
    BofA Securities
    10/16/2024$30.00 → $34.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $EXEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development

    – Dr. Aftab has served for over 25 years at Exelixis and has been instrumental in driving the company's scientific innovation and development activities – Exelixis, Inc. (NASDAQ:EXEL) today announced it has appointed Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. In this new role, Dr. Aftab will oversee all aspects of the company's drug discovery, translational research, product development and medical affairs activities. "Dana has been an integral part of the Exelixis team for more than 25 years, with deep expertise that spans the drug discovery and development continuum. He's been a key contributor to many of Exelixis' most important milestones, inclu

    8/29/25 5:47:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

    – Presentations to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: 2025 Wells Fargo Healthcare Conference: Exelixis is scheduled to present at 12:45 p.m. ET / 9:45 a.m. PT on Wednesday, September 3 in Everett, MA. Citi's 2025 Biopharma Back to School Conference: Exelixis is scheduled to present at 3:15 p.m. ET / 12:15 p.m. PT on Wednesday, September 3 in Boston. Morgan Stanley 23rd Annual Global Healthcare Conference: Exelixis is scheduled to present at 8:30 a.m. ET / 5:30 a.m. PT on Tuesday, September 9 in New York City. H.C. Wainwright

    8/27/25 4:05:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update

    - Total Revenues of $568.3 million, Cabozantinib Franchise U.S. Net Product Revenues of $520.0 million - - GAAP Diluted EPS of $0.65, Non-GAAP Diluted EPS of $0.75 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the second quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "Exelixis continued to execute on our corporate objectives in the second quarter of 2025, delivering on key commercial, development and pipeline milestones," said Michael M. Morrissey, Ph.D., President and Chief Executiv

    7/28/25 4:05:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eckhardt Sue Gail sold $805,140 worth of shares (18,838 units at $42.74), decreasing direct ownership by 47% to 21,380 units (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    6/4/25 7:57:38 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Wyszomierski Jack L sold $324,683 worth of shares (7,535 units at $43.09), decreasing direct ownership by 2% to 358,882 units (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    6/4/25 7:57:28 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Johnson David Edward

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    6/2/25 5:22:46 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Exelixis downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Exelixis from Outperform to Sector Perform and set a new price target of $50.00 from $45.00 previously

    7/8/25 9:52:19 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exelixis upgraded by Stephens with a new price target

    Stephens upgraded Exelixis from Equal-Weight to Overweight and set a new price target of $60.00

    6/24/25 7:50:32 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exelixis downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Exelixis from Overweight to Equal Weight and set a new price target of $36.00

    2/24/25 7:08:46 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for CABOMETYX issued to EXELIXIS INC

    Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-16) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/20/2023. Application Category: NDA, Application Number: 208692, Application Classification: Labeling

    9/21/23 4:37:02 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for CABOMETYX issued to EXELIXIS INC

    Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-14) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 07/14/2022. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy

    7/15/22 4:38:40 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for CABOMETYX issued to EXELIXIS INC

    Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-12) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/17/2021. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy

    9/20/21 3:53:29 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Johnson David Edward bought $8,733,955 worth of shares (425,000 units at $20.55) (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    5/30/24 7:50:14 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Johnson David Edward bought $3,932,734 worth of shares (190,000 units at $20.70) (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    2/22/24 5:08:50 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Johnson David Edward sold $2,602,038 worth of shares (120,409 units at $21.61) and bought $2,602,038 worth of shares (120,409 units at $21.61) (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    11/29/23 4:30:29 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    SEC Filings

    View All

    Exelixis Inc. filed SEC Form 8-K: Leadership Update

    8-K - EXELIXIS, INC. (0000939767) (Filer)

    8/29/25 5:10:41 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Exelixis Inc.

    10-Q - EXELIXIS, INC. (0000939767) (Filer)

    7/28/25 4:31:54 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exelixis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - EXELIXIS, INC. (0000939767) (Filer)

    7/28/25 4:09:07 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    Financials

    Live finance-specific insights

    View All

    Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update

    - Total Revenues of $568.3 million, Cabozantinib Franchise U.S. Net Product Revenues of $520.0 million - - GAAP Diluted EPS of $0.65, Non-GAAP Diluted EPS of $0.75 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the second quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "Exelixis continued to execute on our corporate objectives in the second quarter of 2025, delivering on key commercial, development and pipeline milestones," said Michael M. Morrissey, Ph.D., President and Chief Executiv

    7/28/25 4:05:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025

    – Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its second quarter 2025 financial results will be released on Monday, July 28, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Eve

    7/14/25 4:05:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

    - Total Revenues of $555.4 million, Cabozantinib Franchise U.S. Net Product Revenues of $513.3 million - - GAAP Diluted EPS of $0.55, Non-GAAP Diluted EPS of $0.62 - - Increasing 2025 Full Year Net Product Revenues and Total Revenues Guidance by $100 million - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by accelerating growth in CABOMETYX® d

    5/13/25 4:07:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Exelixis Inc. (Amendment)

    SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)

    5/8/24 4:11:20 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Exelixis Inc.

    SC 13G - EXELIXIS, INC. (0000939767) (Subject)

    2/13/24 9:19:48 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Exelixis Inc. (Amendment)

    SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)

    6/2/23 5:05:24 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    Leadership Updates

    Live Leadership Updates

    View All

    Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development

    – Dr. Aftab has served for over 25 years at Exelixis and has been instrumental in driving the company's scientific innovation and development activities – Exelixis, Inc. (NASDAQ:EXEL) today announced it has appointed Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. In this new role, Dr. Aftab will oversee all aspects of the company's drug discovery, translational research, product development and medical affairs activities. "Dana has been an integral part of the Exelixis team for more than 25 years, with deep expertise that spans the drug discovery and development continuum. He's been a key contributor to many of Exelixis' most important milestones, inclu

    8/29/25 5:47:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

    Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo

    7/8/25 10:25:00 AM ET
    $CELC
    $CTOR
    $EXEL
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS

    TORONTO, Oct. 9, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE:AIAI) (OTCQB:AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, is pleased to announce the appointment of P.J. Haley, Executive Vice President, Commercial at Exelixis, Inc. (NASDAQ:EXEL), as a director of the Company, effective October 15th, 2024. Mr. Haley will be replacing Sheetal Jaitly, who is stepping down as a director after a period of dedicated service and contributions to the Company. As NetraMark focuses on advancing its technology for late phas

    10/9/24 8:30:00 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care